[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628026":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":38,"responsibleParty":51,"collaborators":26,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":26,"enrollmentInfo":62,"targetDuration":26,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":74,"whyStopped":26,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Hospital Universitari Vall d'Hebron Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Early discharge (24 hours post-TAVI)","EXPERIMENTAL","Patients will be discharged from the hospital 24 hours post-TAVI with PhysioMem PM 100 4G ambulatory monitoring system.",[13],"Device: PhysioMem PM 100 4G ambulatory monitoring system",{"label":15,"type":16,"description":17,"interventionNames":18},"Discharge according Standard Care","ACTIVE_COMPARATOR","Patients will be discharged from the hospital according standard care",[19],"Behavioral: Standard care",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BEHAVIORAL","Standard care","Patients discharged according to standard care",[15],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"DEVICE","PhysioMem PM 100 4G ambulatory monitoring system","Patients discharged with PhysioMem PM 100 4G ambulatory monitoring system",[9],[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Bruno García del Blanco, MD, PhD","CONTACT","00342746155","bruno.garcia@vallhebron.cat",[39],{"facility":40,"status":26,"city":41,"state":26,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":26},"Hospital Unniversitari Vall d'Hebron","Barcelona","08035","Spain","ES",{"type":46,"coordinates":47},"Point",[48,49],2.15899,41.38879,{"lat":49,"lon":48},{"type":52,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100628026","evaluation-of-the-non-invasive-electrocardiographic-monitoring-strategy-associated-with-early-discharge-in-patients-with-conduction-disorder-through-tavi-implantation-100628026",false,"NCT07456280","Evaluation of the Non-invasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With Conduction Disorder Through TAVI Implantation","IMPROVE","Inclusion Criteria:\n\nAll inclusion criteria must be met\n\n* Age ≥ 18 years and\n* Undergone successful transfemoral or transaortic TAVI for severe aortic stenosis and\n* Presence of at least one of the following conduction disorders and\n* Pre-procedural basal conduction disorder (e.g., right\u002Fleft bundle branch block, bifascicular block, IVCD) with QRS between 120-160 msec.\n* De novo conduction disorder after TAVI (de novo bundle branch block) with QRS between 120-160 msec.\n* Clinical stability at 24 hours post-procedure and\n* Capacity to give informed consent.\n\nExclusion Criteria:\n\nNo exclusion criteria must be met\n\n* Immediate indication for permanent pacemaker following the procedure.\n* Persistent complete atrioventricular block.\n* QRS \\>160 msec and\u002For PR prolongation.\n* Haemodynamic instability or complications of TAVI (major bleeding, stroke, decompensated heart failure) that contraindicate early discharge.\n* Technical or clinical impossibility of using the PhysioMem PM 1004G monitoring system.\n* Life expectancy \\\u003C 12 months due to non-cardiovascular comorbidity.\n* Refusal or inability to undergo outpatient follow-up.\n* Pregnant or breastfeeding.","ALL","18 Years",{"count":63,"type":64},100,"ESTIMATED","INTERVENTIONAL",[67],"NA","Study to evaluate the efficacy and safety of a non-invasive electrocardiographic monitoring strategy associated with early discharge in patients with conduction disorder after transfemoral TAVI implantation, and its potential benefits compared to standard care.",[70,71],"Severe Aortic Valve Stenosis","Cardiovascular Diseases",[73],"TAVI(Transcatheter Aortic Valve Implantation)","NOT_YET_RECRUITING","2026-03-04",{"date":77,"type":78},"2026-03-06","ACTUAL",{"date":80,"type":64},"2026-04-01",{"date":82,"type":64},"2028-08-01",{"name":5,"class":6},1]